Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2019
Currency: Indian Rupees (INR) with U.S. Dollar (USD) convenience translation (Rate: $1.00 = Rs. 71.36)
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Principal markets include India, the United States, Russia, the United Kingdom, and Germany.
Key Financial Metrics
| Metric (in millions) | 9 Months Ended Dec 31, 2019 | 3 Months Ended Dec 31, 2019 |
|---|---|---|
| Revenues | Rs. 130,282 (U.S.$ 1,826) | Rs. 43,838 (U.S.$ 614) |
| Gross Profit | Rs. 71,201 (54.7% margin) | Rs. 23,722 (54.1% margin) |
| Net Profit/(Loss) | Rs. 11,856 (U.S.$ 166) | Rs. (5,697) (U.S.$ (80)) |
| Operating Cash Flow | Rs. 27,295 (U.S.$ 382) | N/A |
| Total Assets | Rs. 217,898 (U.S.$ 3,054) | N/A |
| Total Liabilities | Rs. 69,226 (U.S.$ 970) | N/A |
| Shareholders' Equity | Rs. 148,672 (U.S.$ 2,083) | N/A |
| Short-term Borrowings | Rs. 9,114 (U.S.$ 128) | N/A |
| Long-term Borrowings | Rs. 7,206 (U.S.$ 101) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 15% for the nine months ended Dec 31, 2019, compared to the prior year. The Global Generics segment grew 10%, driven by new product launches and volume increases, partially offset by price erosion. The PSAI segment grew 7%.
- Profitability Decline: Net profit for the nine months decreased 18% to Rs. 11,856 million. The quarter ended Dec 31, 2019, reported a net loss of Rs. 5,697 million, a reversal from a profit of Rs. 4,852 million in the same period in 2018.
- Impairment Charges: A significant non-cash impairment charge of Rs. 16,760 million was recognized for the nine months ended Dec 31, 2019 (Rs. 13,200 million in Q4 alone). This was primarily due to the impairment of intangible assets related to the gNuvaring product (Rs. 11,137 million) and other product-related intangibles due to adverse market conditions and price erosion.
- Divestiture Impact: Revenues from Proprietary Products increased 255% year-over-year for the nine-month period, largely due to a one-time license fee of Rs. 7,486 million from the sale of rights for ZEMBRACE SYMTOUCH and TOSYMRA to Upsher-Smith Laboratories.
- Tax Benefit: The company recognized a tax benefit of Rs. 966 million for the nine months, compared to an expense of Rs. 2,141 million in the prior year. This was driven by deferred tax assets related to impairment losses and a reduction in India's Minimum Alternate Tax (MAT) rate.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Impairment: Significant write-downs on intangible assets (gNuvaring, tobramycin, ramelteon, imiquimod) due to competitive pressures and lower-than-expected performance.
- Ranitidine Recall: The company initiated a voluntary recall of all ranitidine products in the U.S. due to NDMA contamination. Inventory write-downs of Rs. 231 million and a provision for refund liabilities of Rs. 170 million were recognized.
- Settlement Income: Received Rs. 3,457 million from Celgene as a settlement regarding a generic version of REVLIMID.
- Legal and Regulatory Risks:
- Antitrust Litigation: DRL is a defendant in multiple U.S. antitrust class actions (MDL-2724) alleging price-fixing and bid-rigging in the generic pharmaceutical market. The company denies wrongdoing.
- Patent Litigation: Ongoing disputes with Indivior regarding Suboxone sublingual film patents. The company has filed counterclaims alleging anticompetitive conduct.
- Ranitidine Litigation: Named in class action lawsuits regarding NDMA exposure; the company intends to defend vigorously.
- Environmental: Ongoing proceedings regarding land and water pollution in India; a remediation fee demand was stayed by the High Court pending deposit.
- Outlook: Management highlights continued growth in Global Generics through new product launches (22 new products in North America in the nine-month period) and expansion in emerging markets. However, price erosion in key markets remains a headwind.
Investor Verification Checklist
- Impairment Sustainability: Verify the assumptions used in the discounted cash flow models for the gNuvaring and other intangible asset impairments to assess if further write-downs are likely.
- Ranitidine Liability: Monitor the status of the ranitidine recall and associated litigation to estimate potential future costs beyond the current provisions.
- Antitrust Exposure: Review the scope of the U.S. antitrust multi-district litigation (MDL-2724) and the specific drugs implicated to gauge potential financial exposure.
- Regulatory Compliance: Track the status of U.S. FDA inspections, particularly the recent Form 483 issued to the Srikakulam API plant, to ensure no export bans or further restrictions occur.
- Divestiture Proceeds: Confirm the realization of contingent milestone payments from the Upsher-Smith transaction.